1 February 2010PatentsEduardo Castillo & Ana Bayó

A step too far? Generic drugs price fixing and Spain's Medicines Act

Spain’s Medicine Act was amended in December 2009. The Ministry of Health and Consumer Affairs is responsible for deciding if a generic drug will be financed by the National Health System and, if so, for fixing the industrial price and public retail price at which the medicine can be sold.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

‘We created law’: G1/24 and the creation of the ‘diamond standard’

Tech litigators join Hogan Lovells’ Paris practice from A&O Shearman

How in-house patent pros are ‘enablers of innovation’

Smart IP for startups: how to avoid the common traps

Defending the realm: How a key MoD supplier crafts its IP strategy

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

AI patent trends signal tomorrow’s technologies

WATCH: Section 112 – Where has the dust settled?

A step too far? Generic drugs price fixing and Spain's Medicines Act

Editor's picks

Editor's picks

More articles